CCO Treatment Updates

Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate

Virtual Presentations

Anthracyclines Should Remain a Mainstay of Adjuvant Chemotherapy

Program Director: Fran Visco, JD

Faculty:

Mark Levine, MD

CREDIT INFORMATION

Release Date: 02/10/09

Expiration Date: 02/09/10

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Mark Levine, MD, reviews clinical trial data supporting the use of anthracyclines in adjuvant breast cancer therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize the findings of clinical trials comparing the use of anthracycline-containing vs nonanthracycline-containing regimens as adjuvant therapy for early breast cancer
Describe efficacy and safety data from clinical trials evaluating anthracycline-containing regimens vs nonanthracycline-containing regimens in early breast cancer
Analyze outcomes of recent clinical trials data assessing HER2 and topoisomerase II as predictive biomarkers of response to anthracyclines in early breast cancer

Slideset: Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate

Downloadable slideset on clinical trial data and studies supporting the use of anthracyclines in adjuvant breast cancer therapy.

Format: Microsoft PowerPoint (.ppt) | File size: 3.22 MB | Date posted: 2/3/2009

The Use of Nonanthracycline-Based Regimens in Early Breast Cancer

Program Chair: Fran Visco, JD

Faculty:

Dennis J. Slamon, MD, PhD

CREDIT INFORMATION

Release Date: 02/17/09

Expiration Date: 02/16/10

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Dennis J. Slamon, MD, PhD, discusses the use of nonanthracycline-based regimens to treat patients with early breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss clinical trial results supporting the use of nonanthracycline-containing regimens for treating early breast cancer patients
Describe the role of topoisomerase II alpha in determining HER2 sensitivity to anthracyclines in early breast cancer
Explain the implication of HER2 status in determining the best treatment option for early breast cancer patients

Slideset: The Use of Nonanthracycline-Based Regimens in Early Breast Cancer

Downloadable slideset on clinical trial data and studies supporting the use of nonanthracycline-based regimens to treat patients with early breast cancer.

Format: Microsoft PowerPoint (.ppt) | File size: 7.04 MB | Date posted: 2/11/2009

Audio Archive

Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate

In this expert debate, Mark Levine, MD, and Dennis J. Slamon, MD, PhD, weigh the value and risks of anthracycline use in early breast cancer.

Audio File 28.9 MB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.